Atrial Fibrillation Occurring Transiently With Stress (AFOTS)

CompletedOBSERVATIONAL
Enrollment

281

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

November 30, 2022

Conditions
Atrial Fibrillation New Onset
Interventions
DIAGNOSTIC_TEST

14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)

The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).

Trial Locations (3)

Unknown

Hamilton General Hospital, Hamilton

Juravinski Hospital, Hamilton

St. Joseph's Health Centre, Hamilton

All Listed Sponsors
collaborator

Canadian Cardiovascular Society

OTHER

collaborator

Canadian Stroke Prevention Intervention Network

OTHER

lead

Population Health Research Institute

OTHER